この度、イギリスFrancis Crick Institute/King’s College London の Adrian Hayday 博士
(Principal Research Scientist, Francis Crick Institute /Professor of Immunobiology, King’s College London）を講師にお迎えし、
2023年8月2日(水) 16：00～ CiRA講堂にてセミナーを開催することとなりました。
博士は、ガンマデルタT細胞とそれを活用したがん免疫療法の開発において第一線で活躍されている研究者です。
ご興味のある方は是非ご参加ください。
皆さまのご参加を心よりお待ち申し上げております。
※秘書の皆様におかれましては、本案内を研究室内でご回覧いただけますと幸いです。
This is an announcement of the CiRA seminar which you are warmly invited to join.
We would be grateful if you could please distribute this event notice to you.
We are inviting Prof. Adrian Hayday（Principal Research Scientist, Francis Crick Institute/Professor of Immunobiology, King’s College London）as a guest speaker in a following upcoming seminar.
We sincerely look forward to your participation.
開催日
-
2023/8/2
16:00-17:00
開催場所（方法）
CiRA講堂 (CiRA本館１階 講堂) [15:45から入室可] ※参加申し込み不要。当日直接CiRA講堂にお越しください。
Onsite at CiRA, Bldg. I, Auditorium
詳細
【講演者】Prof. Adrian Hayday（Principal Research Scientist, Francis Crick Institute /Professor of Immunobiology, King’s College London）
【タイトル】Clinically practical T cell immunotherapies recognising cell status rather than neoantigens
【講演要旨】
Current approaches to cancer immunotherapy borrow directly from antigen-specific, adaptive CD8 T cell responses to virus infection. In cancers such as those induced by papilloma viruses or Epstein Barr virus, the antigens are viral peptides presented by MHC, whereas in other cancers, “neo-antigens” are derived from autologous proteins mutated as a result of genome instability. Therapeutic “checkpoint inhibitors” promote such T cell responses and can be highly efficacious. However, they are also efficacious in tumours lacking MHC and/or with low mutational burden that are therefore not suited to ab T cell surveillance. These favourable clinical outcomes reflect an alternative means of tumour-targeting mediated by gd T cells that recognise combinatorial markers of cell pathology rather than specific antigens. Central to this recognition is the unique property of the gd T cell receptor (TCR) which can actively distinguish cancerous cells, using clonotypic recognition, from healthy cells which are detected by using TCRgd as an innate receptor. This property translates to a natural and practical therapeutic window that can explain promising clinical results from the direct application of gd T cells as cancer therapeutics, either unmodified or coupled to CAR-T. The presentation will focus on the underlying immunological mechanisms and their practical application.
【Speaker】Prof. Adrian Hayday（Principal Research Scientist, Francis Crick Institute/Professor of Immunobiology, King’s College London）
【Title】 Clinically practical T cell immunotherapies recognising cell status rather than neoantigens
【Abstract】
Current approaches to cancer immunotherapy borrow directly from antigen-specific, adaptive CD8 T cell responses to virus infection. In cancers such as those induced by papilloma viruses or Epstein Barr virus, the antigens are viral peptides presented by MHC, whereas in other cancers, “neo-antigens” are derived from autologous proteins mutated as a result of genome instability. Therapeutic “checkpoint inhibitors” promote such T cell responses and can be highly efficacious. However, they are also efficacious in tumours lacking MHC and/or with low mutational burden that are therefore not suited to ab T cell surveillance. These favourable clinical outcomes reflect an alternative means of tumour-targeting mediated by gd T cells that recognise combinatorial markers of cell pathology rather than specific antigens. Central to this recognition is the unique property of the gd T cell receptor (TCR) which can actively distinguish cancerous cells, using clonotypic recognition, from healthy cells which are detected by using TCRgd as an innate receptor. This property translates to a natural and practical therapeutic window that can explain promising clinical results from the direct application of gd T cells as cancer therapeutics, either unmodified or coupled to CAR-T. The presentation will focus on the underlying immunological mechanisms and their practical application.
申し込み
不要
参加費
なし ／ Free
お問い合わせ
主催・連絡先：CiRA 濱崎研究室
E-mail: hamazaki-g@cira.kyoto-u.ac.jp
Tel: 075-366-7327
京都大学iPS細胞研究所
未来生命科学開拓部門 濱崎 洋子（代理送信：秘書 米村 綾）
Yoko Hamazaki
CiRA, Kyoto University
(Sent by Aya Yonemura)
Contact / hamazaki-g@cira.kyoto-u.ac.jp